Close

SPPI Balance Sheet

Click line-items for a historical chart and %
Cash and cash equivalents 110.29M
Marketable securities 38.6M
Accounts receivable, net of allowance for doubtful accounts of $630 and $339, respectively 47.77M
Inventories, net 10.29M
Prepaid expenses and other current assets 571K
Total current assets 207.52M
Investments 11.88M
Property and equipment, net 2.82M
Intangible assets, net 43.08M
Other assets 576K
TOTAL ASSETS 265.87M
Accounts payable and other accrued obligations 50.05M
Accrued compensation and related expenses 3.64M
Deferred revenue 12.3M
Common stock warrant liability 0
Accrued drug development costs 9.56M
Total current liabilities 75.55M
Capital lease obligations 17K
Deferred revenue and other credits--less current portion 16.17M
Zevalin related contingent obligations 298K
Total liabilities 92.04M
Commitments and contingencies 0
Stockholders' Equity:
Preferred stock value 0
Common stock, $0.001 par value--175,000,000 shares authorized; 52,947,221 and 51,459,284 issued and outstanding at June 30, 2011 and December 31, 2010, respectively 57K
Additional paid-in capital 446.8M
Accumulated other comprehensive loss -147K
Accumulated deficit -270.16M
Total stockholders' equity 173.83M
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 265.87M
Stockholders' Equity:
Preferred stock value 123K

Entities mentioned with SPPI

View All Entities